ICON Public Limited Company

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-20 pm EDT			5-day change	1st Jan Change
146.48 ^USD	+2.02%		+0.56%	-30.15%

May. 23	Trump's Tariff Blitz Roils Markets, Targets EU and Apple
May. 23	Analyst recommendations: Crowdstrike, AMD, Boeing, Intuit, Okta…

Truist Securities Adjusts Price Target on ICON to $190 From $208, Keeps Buy Rating

Published on 05/05/2025 at 14:08

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about ICON Public Limited Company

Trump's Tariff Blitz Roils Markets, Targets EU and Apple	May. 23
Analyst recommendations: Crowdstrike, AMD, Boeing, Intuit, Okta…	May. 23
Truist Securities Adjusts Price Target on ICON to $190 From $208, Keeps Buy Rating	May. 05	MT
Deutsche Bank Adjusts ICON Price Target to $200 From $235, Maintains Buy Rating	May. 01	MT
ICON Seeks M&A Opportunities	May. 01	CI
ICON Public Limited Company, Q1 2025 Earnings Call, May 01, 2025	May. 01
Icon Q1 Adjusted Earnings, Revenue Fall	Apr. 30	MT
Icon Reports First Quarter 2025 Results	Apr. 30	RE
Earnings Flash (ICLR) ICON PLC Reports Q1 Adjusted EPS $3.19, vs. FactSet Est of $3.10	Apr. 30	MT
Earnings Flash (ICLR) ICON PLC Posts Q1 Revenue $2B, vs. FactSet Est of $2.01B	Apr. 30	MT
Tranche Update on ICON Public Limited Company's Equity Buyback Plan announced on February 19, 2025.	Apr. 30	CI
Tranche Update on ICON Public Limited Company's Equity Buyback Plan announced on October 25, 2024.	Apr. 30	CI
Icon Public Limited Company Updates Earnings Guidance for Full Year 2025	Apr. 30	CI
ICON Public Limited Company Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 30	CI
Analyst recommendations: Meta Platforms, Progressive, Equifax, SBA Communications, Cadence Design Systems...	Apr. 29
JPMorgan Downgrades ICON to Neutral From Overweight, Adjusts Price Target to $150 From $265	Apr. 29	MT
BofA Securities Cuts Price Target on ICON to $204 From $255	Apr. 14	MT
Lost in tariffs	Apr. 14
TD Cowen Downgrades ICON to Hold From Buy, Adjusts Price Target to $157 From $254	Apr. 14	MT
Analyst recommendations: Apple, Blackstone, Estee Lauder, Mongodb, Stellantis…	Apr. 14
Truist Adjusts ICON's Price Target to $208 From $262, Keeps Buy Rating	Apr. 10	MT
Barclays Downgrades ICON to Equalweight From Overweight, Adjusts Price Target to $165 From $240	Apr. 10	MT
Telix Pharmaceuticals Limited Announces Appointment of Anne Whitaker as A Non-Executive Director Based in the United States, Effective 7 April 2025	Apr. 03	CI
ICON Public Limited Company's Equity Buyback announced on October 25, 2024, has closed with 1,360,537 shares, representing 1.68% for $250 million.	Mar. 30	CI
Goldman Sachs Downgrades ICON to Neutral From Buy, Cuts Price Target to $200 From $250	Mar. 21	MT

Chart ICON Public Limited Company

Duration

Period

ICLR: Dynamic Chart

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

Employees

41,250

Sector

Biotechnology & Medical Research

Calendar

Jul. 22 - Q2 2025 Earnings Release (Projected)

More about the company